Gleacher Shacklock has approximately 40 staff including its partners.
Dr Anthony Hartley is a partner at Gleacher Shacklock leading the Healthcare business.
Anthony has over 23 years of investment banking experience advising major European healthcare companies on a range of strategic, financial and M&A transactions across the pharmaceutical, biotechnology, generics and consumer health sectors.
Representative transactions include advising GSK on their Consumer Health JV with Pfizer and its subsequent spin-off to form Haleon, Roche on its stake buy-back from Novartis, Bain & Cinven on their acquisition of Stada Arzneimittel, Hikma on their acquisition of Roxane generics from Boehringer Ingelheim, Bayer on the sale of their Dr Scholls franchise to Yellow Wood Partners and Coppertone franchise to Beiersdorf, Johnson Matthey on the sale of its healthcare division to Altaris Capital, and Morningside on its sale to Aspire Pharmaceuticals.
Prior to joining Gleacher Shacklock, Anthony was EMEA Head of Healthcare Investment Banking at Citi, before which he worked at UBS as Head of European Pharmaceuticals having joined from Morgan Stanley. Prior to investment banking, Anthony held a variety of research and operational roles at Pfizer, GSK and AstraZeneca.
Anthony has a D.Phil in Pharmacology from Oxford University and an MBA with Distinction from Manchester Business School.
